Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Probiotic pill tested to stop weight regain after GLP-1s

NCT ID NCT07209046

Disease control Sponsor: Metagenics, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a daily probiotic supplement (UltraFlora Triplebiotic) can help adults avoid regaining weight after they stop taking GLP-1 medications like Ozempic or Wegovy. About 128 people who recently stopped GLP-1 treatment will take the supplement or a placebo for 3 months. The main goal is to see if the supplement reduces weight regain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 128 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2025

An estimate. Start dates often move.

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Providing written informed consent 2. Males and females of at least 18 years old 3. Body mass index (BMI) between 25 and 30 (including 25 and 30) (Weight: 25 \< BMI \< 30) 4. Having undergone treatment with GLP-1 for more than 3 months but for less than 1 year. 5. Having stopped GLP-1 treatment for a maximum of 4 weeks 6. Being willing to maintain stable dietary habits and physical activity levels throughout the trial period 7. Being willing not to introduce any other food supplements during the trial period (supplements used in the two weeks prior to enrolling in the trial and used consistently throughout are acceptable, except for probiotics). Exclusion Criteria: 1. Being on GLP-1 treatment 2. Having had any type of bariatric surgery, or planned bariatric surgery during the period of trial participation. 3. Suffering from a severe chronic disease (e.g., cancer, HIV, hepatic or renal impairment, diabetes type I), inflammatory bowel disease (IBD), Coeliac Disease, and/or being immunocompromised. 4. Suffering from any uncontrolled endocrine disorder. 5. Having consumed any probiotic supplements in the 3 months prior to enrollment. 6. Having used any antibiotic treatment in the 3 months prior to enrollment. 7. Having a known allergy to the ingredients in the study product. 8. Being pregnant or lactating (breastfeeding) or trying to become pregnant. 9. Participating in an other clinical trial. 10. Suffering from dementia or inability to take the trial treatment in an appropriate way. 11. Taking UltraFlora® Triplebiotic or any similar product from competitors prior to trial participation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adults are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adults GLP - 1

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.